Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.

Abstract

Posaconazole (PSC) is currently recommended as primary prophylaxis in neutropenic patients with acute myeloid leukaemia (AML) and in allogenic haematopoietic stem cell transplantation (AHSCT) recipients with graft-versus-host disease (GVHD). Studies focusing on breakthrough invasive fungal disease (IFD) upon PSC prophylaxis show disparate results. In order… (More)
DOI: 10.1111/1469-0691.12688

Topics

Cite this paper

@article{Lerolle2014BreakthroughIF, title={Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.}, author={Nicolas Lerolle and Emmanuel Raffoux and Gerald Socie and Sophie Touratier and H{\'e}l{\`e}ne Sauvageon and Rapha{\"e}l Porcher and Sylvie Roussin Bretagne and Anne Bergeron and Evan M. Azoulay and J. A. Martinez Molina and Mar{\'i}a Mercedes Lafaurie}, journal={Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases}, year={2014}, volume={20 11}, pages={O952-9} }